Guangdong Wanzheng Pharmaceutical

Guangdong Wanzheng Pharmaceutical is a clinical-stage biopharmaceutical company based in Guangzhou, China, dedicated to the discovery and development of innovative small molecule drugs. The company primarily focuses on the oncology sector, aiming to develop Class 1 new drugs that address unmet medical needs in cancer treatment. Its lead candidate, WZ-001, is a novel small molecule inhibitor currently undergoing Phase 1 clinical trials for advanced solid tumors. Wanzheng leverages a robust internal R&D platform that integrates medicinal chemistry and pharmacology to drive its pipeline forward. Located in the Guangzhou International Bio Island, the company benefits from a strategic position within one of China's leading biotech hubs. Wanzheng is committed to delivering high-quality therapeutic options through scientific innovation and rigorous clinical validation.